Picard Advances Patent Protection for Fully Implantable Artificial Heart Technology

Core Insights - Picard Medical, Inc. has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), named "Emperor" [1][2] - The company now holds a total of 34 patented claims in the U.S. related to its next-generation total artificial heart system, with additional protection in China [1][2] - The Emperor is designed to be fully implantable and provide pulsatile flow without the need for an external pneumatic driver [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona, and is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [4] - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the U.S. and Canada [4] - Over 2,100 implants have been performed at hospitals across 27 countries, making the SynCardia Total Artificial Heart the most widely used and extensively studied artificial heart globally [4] Strategic Goals - The company aims to expand its patent portfolio globally to protect its innovative technologies, including durable mechanisms, advanced electronics, and wireless implantable features [2][3] - The patent portfolio is seen as a foundation for the company's future, securing the path from development to commercialization and ensuring long-term global leadership in heart replacement technology [3]